Winstrol
Winstrol
[win´strol]anabolic steroid
A drug or hormone-like substance chemically or pharmacologically related to 17-α-alkylated testosterone that promotes muscle growth, which are commonly abused by athletes. Lipid changes by ASs are more marked with oral stanazol (manufactured for horses) than with IV testosterone; it decreases HDL-C (especially HDL2) and increases hepatic TG lipase (HDL) catabolism.Indications
Children, adolescents with delayed puberty, decreased growth, small penis, hypogonadism, testosterone deficiency, osteoporosis management, aplastic anaemia, endometriosis, angioedema, sports performance enhancement (no longer legal), relief and recovery from common injuries, rehabilitation, weight control, anti-insomnia, and regulation of sexuality, aggression and cognition.
Route
Oral, parenteral.
Metabolic effects
Increased protein synthesis and amino acid consumption, androgenesis, catabolism and gluticocototitosis.
Adverse effects (men)
Breast enlargement (gynecomastia), testicular atrophy, sterility, sperm abnormalities, impotence, prostatic hypertrophy, myocardial hypertrophy and fibrosis, myocardial infarction and fatal arrhythmias, peliosis hepatis, cholestasis, hepatic adenomas, testicular atrophy, peripheral oedema, intracerebral thrombosis.
Adverse effects (women)
Clitoral hypertrophy, beard growth, baldness, deepened voice, decreased breast size.
Adverse effects (men and women)
Aggression and antisocial behavior, increased risk of cardiovascular disease, peliosis hepatis, haemorrhage, jaundice, acne, accelerated bone maturation resulting in short stature, liver tumours (hepatic adenomas and CA) which may regress with abstinence; AS abusers are at an increased risk for HIV transmission, given the common practice of sharing of needles when injecting ASs.
Lab
ASs are detectable to 1 parts per billion 4 days after last use if the hormone is water-soluble, or 14 days after use in lipid-soluble compounds.
FDA status
ASs are schedule-III drugs per the Controlled Substances Act.